The BRENDA model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders

Journal of Psychiatric Practice

Volumn 12, Issue 2, 2006, Pages 80-89

  Starosta, Aron N ^a   Leeman, Robert F ^a   Volpicelli, Joseph R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acamprosate; Alcohol use disorder; BRENDA program; Disulfiram; Naltrexone; Treatment compliance

Indexed keywords

ACAMPROSATE; ANTIDEPRESSANT AGENT; DISULFIRAM; METHADONE; NALTREXONE; OXAZEPAM; DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; NARCOTIC ANTAGONIST; TAURINE;

ALCOHOL CONSUMPTION; ALCOHOL REHABILITATION PROGRAM; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRINKING BEHAVIOR; DRUG DEPENDENCE; EMPATHY; HEALTH CARE; HEALTH CARE NEED; HUMAN; MEDICAL DOCUMENTATION; MEDICAL PERSONNEL; MEDICAL SERVICE; MENTAL HEALTH; METHADONE TREATMENT; NAUSEA; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DISORDER; PSYCHOSOCIAL REHABILITATION; PSYCHOTHERAPY; SOCIAL INTERACTION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; ADULT; ATTITUDE TO HEALTH; CASE REPORT; MALE; METHODOLOGY; PSYCHOLOGICAL THEORY; PSYCHOLOGY; STATISTICS;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; ATTITUDE TO HEALTH; DISULFIRAM; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; PSYCHOLOGICAL THEORY; PSYCHOLOGY; PSYCHOTHERAPY; TAURINE;

EID: 33745624345     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200603000-00003     Document Type: Article

References (71)

1. Substance Abuse and Mental Health Services Administration. Overview of findings from the 2004 National Survey on Drug Use and Health. 2005;Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061. Rockville, MD (www.oas.samhsa.gov/nsduh/2k4nsduh/2k4tabs/2k4tabs.pdf).
2. Kranzler HR. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol Alcohol 2000;35:537-47.
3. Aalto M, Seppa K, Mattila P, et al. Brief intervention for male heavy drinkers in routine general practice: A three-year randomized controlled study. Alcohol Alcohol 2001;36:224-30.
4. Fleming MF, Barry KL, Manwell LB, et al. Brief physician advice for problem alcohol drinkers: A randomized controlled trial in community-based primary care practices. JAMA 1997;277:1039-45.
5. Ockene JK, Adams A, Hurley TG, et al. Brief physician- and nurse practitioner-delivered counseling for high-risk drinkers: Does it work? Arch Intern Med 1999;159:2198-205.
6. Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:557-68.
7. Kaner EF, Heather N, McAvoy BR, et al. Intervention for excessive alcohol consumption in primary health care: Attitudes and practices of English general practitioners. Alcohol Alcohol 1999;34:559-66.
8. Millstein SG, Marcell AV. Screening and counseling for adolescent alcohol use among primary care physicians in the United States. Pediatrics 2003;111:114-22.
9. Spandorfer JM, Israel Y, Turner BJ. Primary care physicians' views on screening and management of alcohol abuse: Inconsistencies with national guidelines. J Fam Pract 1999;48:899-902.
10. Harris KM, DeVries A, Dimidjian K. Trends in naltrexone use among members of a large private health plan. Psychiatr Serv 2004;55:221.
11. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 1999;281:1318-25.
12. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res 2001;25:1335-41.
13. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001;36:2-10.
14. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2004;CD001867.
15. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol Alcohol 2001;36:544-52.
16. Swift RM. Medications and alcohol craving. Alcohol Res Health 1999;23:207-13.
17. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482-90.
18. Swift RW. Medications. In: Hester RK, Miller WR, eds. Handbook of alcoholism treatment approaches. Boston: Allyn & Bacon; 2002:259-81.
19. Mark TL, Kranzler HR, Poole VH, et al. Barriers to the use of medications to treat alcoholism. Am J Addict 2003;12:281-94.
20. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95.
21. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 1998;22:1300-11.
22. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry 1997;54:737-42.
23. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence: A placebo-controlled trial. Neuropsychopharmacology 2000;22:493-503.
24. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 1992;49:881-7.
25. Volpicelli JR, Pettinati HM, McLellan AT, et al. Combining medication and psychosocial treatments for addictions: The BRENDA approach. New York: The Guilford Press; 2001.
26. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict 2001;10:258-68.
27. Pettinati HM, Volpicelli JR, Pierce JD, Jr, et al. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71-83.
28. Garbutt JC, Kranzler HR, O'Malley SS. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 2005;293:1617-25.
29. Johnson BA, Ait-Daoud NA, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004;1356-61.
30. Sleszynski SL, Glonek T, Kuchera WA. Standardized medical record: A new outpatient osteopathic SOAP note form: Validation of a standardized office form against physician's progress notes. J Am Osteopath Assoc 1999;99:516-29.
31. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and cooccurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-16.
32. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-5.
33. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275:761-7.
34. Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: Results of a placebo-controlled trial. J Clin Psychopharmacol 2003;23:553-62.
35. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders: Implications for national health care. Arch Gen Psychiatry 1996;53:727-35.
36. Havassy BE, Hall SM, Wasserman DA. Social support and relapse: Commonalities among alcoholics, opiate users and cigarette smokers. Addict Behav 1991;16:235-46.
37. Miller WR, Wilbourne PL, Hettema JE. What works? A summary of alcohol treatment outcome research. In: Hester RK, Miller WR, eds. Handbook of alcoholism treatment approaches. Boston: Allyn & Bacon; 2002:13-63.
38. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: A review. Addiction 1993;88:315-35.
39. Roeloffs CA, Fink A, Unutzer J, et al. Problematic substance use, depressive symptoms, and gender in primary care. Psychiatr Serv 2001;52:1251-3.
40. Boekeloo BO, Bobbin MP, Lee WI, et al. Effect of patient priming and primary care provider prompting on adolescent-provider communication about alcohol. Arch Pediatr Adolesc Med 2003;157:433-9.
41. Walsh DC, Hingson RW, Merrigan DM, et al. The impact of a physician's warning on recovery after alcoholism treatment. JAMA 1992;267:663-7.
42. Kristenson H, Ohlin H, Hulten-Nosslin MB, et al. Identification and intervention of heavy drinking in middle-aged men: Results and follow-up of 24-60 months of long-term study with randomized controls. Alcohol Clin Exp Res 1983; 7:203-9.
43. Ritter A, Bowden S, Murray T, et al. The influence of the therapeutic relationship in treatment for alcohol dependency. Drug Alcohol Rev 2002;21:261-8.
44. Stiles WB, Shapiro D, Elliott R. Are all psychotherapies equivalent? Am Psychol 1986;32:165-80.
45. Longabaugh R, Morgenstern J. Cognitive-behavioral coping-skills therapy for alcohol dependence: Current status and future directions. Alcohol Res Health 1999;23:78-85.
46. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997;58:7-29.
47. Horvath AO, Luborsky L. The role of the therapeutic alliance in psychotherapy. J Consult Clin Psychol 1993;61:561-73.
48. Miller WR, Taylor CA, West J. Focused versus broad-spectrum behavior therapy for problem drinkers. J Consult Clin Psychol 1980;48:590-601.
49. Connors GJ, DiClemente CC, Dermen KH, et al. Predicting the therapeutic alliance in alcoholism treatment. J Stud Alcohol 2000;61:139-49.
50. Horvath AO, Greenberg LS. The development of the Working Alliance Inventory. In: Greenberg LS, Pinsof WM, eds. The psychotherapeutic process: A research handbook. New York: Guilford; 1986:529-56.
51. Luborsky L, McLellan AT, Woody GE, et al. Therapist success and its determinants. Arch Gen Psychiatry 1985;42:602-11.
52. Raytek HS, McGrady BS, Epstein EE, et al. Therapeutic alliance and the retention of couples in conjoint alcoholism treatment. Addict Behav 1999;24:317-30.
53. Tunis SL, Delucchi KL, Schwartz K, et al. The relationship of counselor and peer alliance to drug use and HIV risk behaviors in a six-month methadone detoxification program. Addict Behav 1995;20:395-405.
54. Connors GJ, Carroll KM, DiClemente CC, et al. The therapeutic alliance and its relationship to alcoholism treatment participation and outcome. J Consult Clin Psychol 1997;65:588-98.
55. Miller WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles. J Consult Clin Psychol 1993;61:455-61.
56. Rogers CR. A theory of therapy, personality and interpersonal relationships, as developed in the client-centered framework. In: Koch S, ed. Psychology: A study of science. New York: McGraw Hill; 1959:184-256.
57. Carroll KM. Enhancing retention in clinical trials of psychosocial treatments: Practical strategies. NIDA Res Monogr 1997;165:4-24.
58. Denning P. Strategies for implementation of harm reduction in treatment settings. J Psychoactive Drugs 2001;33:23-6.
59. Miller WR, Hester PK. Treating alcohol problems: Toward an informed eclecticism. In: Hester RK, Miller WR, eds. Handbook of alcoholism treatment approaches. Boston: Allyn & Bacon; 2002:1-12.
60. McCaul ME, Svikis DS, Moore RD. Predictors of outpatient treatment retention: Patient versus substance use characteristics. Drug Alcohol Depend 2001;62:9-17.
61. Donovan DM, Kadden RM, DiClemente CC, et al. Client satisfaction with three therapies in the treatment of alcohol dependence: Results from Project MATCH. Am J Addict 2002;11:291-307.
62. Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial. JAMA 2000;283:212-20.
63. Dwight-Johnson M, Unutzer J, Sherbourne C, et al. Can quality improvement programs for depression in primary care address patient preferences for treatment? Med Care 2001;39:934-44.
64. Breslin FC, Sobell MB, Sobell LC, et al. Toward a stepped care approach to treating problem drinkers: The predictive utility of within-treatment variables and therapist prognostic ratings. Addiction 1997;92:1479-89.
65. Murgraff V, White D, Phillips K. Moderating binge drinking: It is possible to change behaviour if you plan it in advance. Alcohol Alcohol 1996;31:577-82.
66. DelBoca FK, Mattson ME. The gender matching hypothesis. In: Longabaugh R, Wirtz PW, eds. Project MATCH hypotheses: Results and causal chain analyses. Bethesda, MD: NIAAA; 2001:186-203.
67. Kadden R, Litt M, Cooney N, et al. Sociopathy as a client-treatment matching variable. In: Longabaugh R, Wirtz PW, eds. Project MATCH hypotheses: Results and causal chain analyses. Bethesda, MD: NIAAA; 2001:98-117.
68. DiClemente CC, Scott CW. Stages of change: Interactions with treatment compliance and involvement. NIDA Res Monogr 1997;165:131-56.
69. Maisto SA, Conigliaro J, McNeil M, et al. The relationship between eligibility criteria for participation in alcohol brief intervention trials and other alcohol and health-related variables. Am J Addict 2001;10:218-31.
70. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997;54:1130-5.
71. O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials. Arch Intern Med 2003;163:1695-704.